FDA Designations Granted to PRAX-222, PRAX-562 for Epileptic Encephalopathies
Source: Pixabay.com

FDA Designations Granted to PRAX-222, PRAX-562 for Epileptic Encephalopathies

According to a recent press release from biopharmaceutical company Praxis Precision Medicines ("Praxis"), two of the company's drug candidates received either Orphan Drug or Rare Pediatric Disease designations for rare…

Continue Reading FDA Designations Granted to PRAX-222, PRAX-562 for Epileptic Encephalopathies
Injectable XP-0863 for Acute Repetitive Seizures Given Fast Track Designation
https://pixabay.com/en/epilepsy-seizure-stroke-headache-623346/

Injectable XP-0863 for Acute Repetitive Seizures Given Fast Track Designation

Recently, specialty pharmaceutical company Xeris Pharmaceuticals ("Xeris") announced that its injectable treatment XP-0863 received Fast Track designation for the treatment of patients with acute repetitive seizures. Xeris created this treatment…

Continue Reading Injectable XP-0863 for Acute Repetitive Seizures Given Fast Track Designation
A Possible Treatment for CDKL5 Deficiency Disorder has Earned Rare Pediatric Disease Designation
source: pixabay.com

A Possible Treatment for CDKL5 Deficiency Disorder has Earned Rare Pediatric Disease Designation

According to a story from BioSpace, the pharmaceutical company Marinus Pharmaceuticals, Inc. announced recently that its investigational product candidate ganaxolone has earned Rare Pediatric Disease designation from the US Food…

Continue Reading A Possible Treatment for CDKL5 Deficiency Disorder has Earned Rare Pediatric Disease Designation
Positive Findings in Phase 2 Study of Refractory Status Epilepticus Drug Candidate
TeroVesalainen / Pixabay

Positive Findings in Phase 2 Study of Refractory Status Epilepticus Drug Candidate

According to a recent press release from the Pennsylvania-based Marinus Pharmaceuticals, the Company is reporting positive results of its phase 2 study of "ganaxolone," an investigational GABAA modulator for patients…

Continue Reading Positive Findings in Phase 2 Study of Refractory Status Epilepticus Drug Candidate

A Nasal Spray Has Just Become the First New Therapy Approved by the FDA for Cluster Seizures in 20 Years

Cluster Seizures Approximately 1/3 of all epilepsy patients live with uncontrolled seizures. Of these, around 150,000 in the United States alone  experience cluster seizures (otherwise known as acute-repetitive seizures, crescendo…

Continue Reading A Nasal Spray Has Just Become the First New Therapy Approved by the FDA for Cluster Seizures in 20 Years
Ganaxolone Shows Potential in Treating CDKL5 and Reveals Biomarker in PCDH19 Epilepsy
stevepb / Pixabay

Ganaxolone Shows Potential in Treating CDKL5 and Reveals Biomarker in PCDH19 Epilepsy

According to a story from globenewswire.com, the biopharmaceutical company Marinus Pharmaceuticals, Inc., recently announced the presentation of Phase 2 clinical trial of the drug ganaxolone as a treatment for CDKL5…

Continue Reading Ganaxolone Shows Potential in Treating CDKL5 and Reveals Biomarker in PCDH19 Epilepsy
A Researcher is Looking Into How Long Artificial Comas Should Last For Status Epilepticus Patients
Bru-nO / Pixabay

A Researcher is Looking Into How Long Artificial Comas Should Last For Status Epilepticus Patients

A researcher from the University of Alabama at Birmingham is working on how to improve treatment for patients with status epilepticus. The original article can be read here, at UAB…

Continue Reading A Researcher is Looking Into How Long Artificial Comas Should Last For Status Epilepticus Patients

Editor’s Choice: It’s Junvenile Arthritis Awareness Month!

Happy Friday! How's the the sweltering heat treating you all (if you're on the east coast of the US, that is)? Hoping you are keeping cool! In the meantime, check out…

Continue Reading Editor’s Choice: It’s Junvenile Arthritis Awareness Month!
Why Status Epilepticus (SE) Drug Therapy Research is Hot News
https://pixabay.com/en/epilepsy-seizure-stroke-headache-623346/

Why Status Epilepticus (SE) Drug Therapy Research is Hot News

Has your healthcare provider ever talked to you about using an FDA-approved drug for an unapproved use (sometimes called an “off-label” use) to treat your disease or medical condition? It…

Continue Reading Why Status Epilepticus (SE) Drug Therapy Research is Hot News
Super-Refractory Status Epilepticus: Could a Ketogenic Diet Help?
https://pixabay.com/en/asparagus-green-green-asparagus-1307604/

Super-Refractory Status Epilepticus: Could a Ketogenic Diet Help?

Status epilepticus is a rare and sometimes fatal condition. About 60 percent of those with this super-refractory status epilepticus (SRSE) die, making it the most dangerous type of seizure. This…

Continue Reading Super-Refractory Status Epilepticus: Could a Ketogenic Diet Help?
Why is She Having a Difficult Time Accessing Marijuana for Seizures and Status Epilepticus?
https://pixabay.com/en/brown-marijuana-pot-stash-weed-20804/

Why is She Having a Difficult Time Accessing Marijuana for Seizures and Status Epilepticus?

Sarah Trask had childhood cancer 32 years ago and had four brain surgeries. Sarah is a survivor. As a result, epilepsy is the side effect she is living with. Sometimes…

Continue Reading Why is She Having a Difficult Time Accessing Marijuana for Seizures and Status Epilepticus?